PHIO PHARMACEUTICALS CORP. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
PHIO PHARMACEUTICALS CORP. (PHIO) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $5.39 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2025-08-14
- PHIO PHARMACEUTICALS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $7.90M.
- PHIO PHARMACEUTICALS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$2.02M.
- PHIO PHARMACEUTICALS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$2.75M.
- PHIO PHARMACEUTICALS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$3.60M, a 119.50% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$3.11M.
- PHIO PHARMACEUTICALS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$3.34M.
- PHIO PHARMACEUTICALS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$12.28M, a 225.10% decline from fiscal 2021.
- PHIO PHARMACEUTICALS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $9.81M, a 34.24% increase from fiscal 2020.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2025-06-30 | $5.39M 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $7.90M 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | -$3.11M 10-K · filed 2025-03-31 | |||
| 2024-09-30 | -$3.10M 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | -$3.79M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$2.02M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$3.34M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$3.37M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$474.00K 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$2.75M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$12.28M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$9.57M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$6.04M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$3.60M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $9.81M 10-K · filed 2023-03-22 | |||
| 2021-09-30 | $12.29M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $15.18M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $18.45M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $7.31M 10-K · filed 2022-03-22 | |||
| 2020-09-30 | $9.93M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $11.93M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $6.35M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$7.95M 10-K · filed 2021-03-25 | |||
| 2019-09-30 | -$6.17M 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | -$4.06M 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | -$2.13M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $11.30M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |